FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2618144711> ?p ?o ?g. }

• W2618144711 endingPage "402" @default.
• W2618144711 startingPage "402" @default.
• W2618144711 abstract "Abstract BACKGROUND Pyruvate kinase (PK) deficiency is a congenital hemolytic anemia caused by deficiency of the glycolytic enzyme red cell PK (PK-R). AG-348 is an orally available, small molecule, allosteric activator of PK-R that activates wild-type and a range of mutated PK-R enzymes in vitro, and increases PK-R activity and restores adenosine triphosphate (ATP) levels in red blood cells from patients with PK deficiency ex vivo. AIMS To describe data from the ongoing DRIVE PK study (NCT02476916), an open-label, dose-ranging trial of AG-348 in transfusion-independent adults with PK deficiency. Early data from this study have been reported (Grace et al. EHA 2016, S466). METHODS After providing informed consent, patients are randomized to AG-348 50 mg or 300 mg orally twice daily (BID) for 6 months. Transfusion independence is defined as no more than 3 units of red blood cells transfused in the 12 months preceding first dose and no transfusions in the 4 months preceding first dose. Patients are followed weekly for Weeks 1-3, then every 3 weeks until Week 12, and then monthly until Week 24. Sex hormone levels and iron status are evaluated at Baseline, Week 12 and End of Study. RESULTS As of the data cutoff date of June 20, 2016, 25 patients have been enrolled and treated for ≥3 weeks. Adverse events (AEs) were mild to moderate. The most frequent AEs were nausea (n=11/25), headache, and insomnia (each n=8/25). One serious AE (Grade 2 osteoporosis) has been reported. Grade 3 AEs were hypertension (n=1), hypertriglyceridemia (n=1), insomnia (n=2), and anemia (n=1). One patient was discontinued from treatment because anemia worsened. There were no Grade 4 AEs and no deaths. Three patients had dose reductions because of headache, nausea, or insomnia. Serum levels of sex steroids were measured at baseline, 12 and 24 weeks; increases in free and total testosterone, and decreases in estradiol and estrone, indicate aromatase inhibition by AG-348, consistent with previously reported results. In 25 patients with ≥3 weeks on treatment, 13 patients (52%) showed a hemoglobin (Hgb) increase >1.0 g/dL (range: 1.2-4.9 g/dL; median: 3.40 g/dL). Three patients had dose reductions because of Hgb values exceeding the protocol-mandated maximum. Hgb responses were typically observed within 2 weeks of treatment and were stable with continued treatment. Two patients had dose increases because of insufficient response to 50 mg. Maximal change in Hgb from baseline according to genotype is shown in Figure 1. Of the 25 enrolled patients with ≥3 weeks on treatment, 6 (24%) had two non-missense mutations and none of these had an Hgb response >1.0 g/dL. Of the 19 patients with at least one missense mutation, 13 (68%) had an Hgb increase exceeding 1.0 g/dL. CONCLUSION AG-348 is a novel, first-in-class, PK-R activator in clinical testing as a disease-altering therapy to improve anemia in patients with PK deficiency. The ongoing DRIVE PK study has now enrolled over 25 patients, and data from additional patients will be available at the time of presentation. Daily dosing with AG-348 is well tolerated and has demonstrated clinically relevant durable increases in Hgb in the majority of the patients with at least 1 missense mutation. Out of the 19 patients with at least one missense mutation, 13 had an Hgb increase of >1.0 g/dL. These data highlight the potential of AG-348 as the first disease-altering treatment for patients with PK deficiency. Figure 1 Maximum hemoglobin (Hgb) increase by genotype Figure 1. Maximum hemoglobin (Hgb) increase by genotype Disclosures Grace: Agios Pharmaceuticals: Other: Scientific Advisor, Research Funding. Rose:Novartis: Honoraria; Celgene: Honoraria; Genzyme: Honoraria. Layton:Novartis: Other: Advisory board meeting; Alexion: Other: Advisory board meeting; GSK: Other: Advisory board meeting; Agios: Speakers Bureau. Yaish:Baxalta: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bayer Healthcare: Consultancy; Octapharma: Consultancy. Barcellini:Agios: Consultancy. Kuo:Agios Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Alexion Pharmaceuticals, Inc: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Apotex: Other: Unrestricted education grant; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Silver:Agios Pharmaceuticals, Inc.: Consultancy. Merica:Agios Pharmaceuticals, Inc.: Employment, Equity Ownership. Kung:Agios Pharmaceuticals, Inc.: Employment, Equity Ownership. Cohen:Agios Pharmaceuticals, Inc.: Consultancy. Yang:Agios Pharmaceuticals, Inc.: Employment, Equity Ownership. Hixon:Agios Pharmaceuticals, Inc.: Equity Ownership, Other: Employment (former); KSQ Therapeutics: Employment, Equity Ownership. Kosinski:Agios Pharmaceuticals, Inc.: Employment, Equity Ownership. Silverman:Agios Pharmaceuticals, Inc.: Employment, Equity Ownership. Dang:Agios Pharmaceuticals, Inc.: Employment, Equity Ownership. Yuan:Agios Pharmaceuticals, Inc.: Employment, Equity Ownership. Barbier:Agios Pharmaceuticals, Inc.: Employment, Equity Ownership. Glader:Agios Pharmaceuticals, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees." @default.
• W2618144711 created "2017-06-05" @default.
• W2618144711 creator A5005354950 @default.
• W2618144711 creator A5007020077 @default.
• W2618144711 creator A5010967094 @default.
• W2618144711 creator A5016689216 @default.
• W2618144711 creator A5016760314 @default.
• W2618144711 creator A5018561595 @default.
• W2618144711 creator A5026279945 @default.
• W2618144711 creator A5026865203 @default.
• W2618144711 creator A5027937488 @default.
• W2618144711 creator A5034535532 @default.
• W2618144711 creator A5044878283 @default.
• W2618144711 creator A5052191965 @default.
• W2618144711 creator A5053330274 @default.
• W2618144711 creator A5055335263 @default.
• W2618144711 creator A5055443458 @default.
• W2618144711 creator A5061423789 @default.
• W2618144711 creator A5061712163 @default.
• W2618144711 creator A5062366315 @default.
• W2618144711 creator A5064622256 @default.
• W2618144711 creator A5077644935 @default.
• W2618144711 creator A5079102665 @default.
• W2618144711 creator A5087973639 @default.
• W2618144711 creator A5090129695 @default.
• W2618144711 date "2016-12-02" @default.
• W2618144711 modified "2023-10-18" @default.
• W2618144711 title "Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study" @default.
• W2618144711 doi "https://doi.org/10.1182/blood.v128.22.402.402" @default.
• W2618144711 hasPublicationYear "2016" @default.
• W2618144711 type Work @default.
• W2618144711 sameAs 2618144711 @default.
• W2618144711 citedByCount "4" @default.
• W2618144711 countsByYear W26181447112017 @default.
• W2618144711 countsByYear W26181447112018 @default.
• W2618144711 countsByYear W26181447112019 @default.
• W2618144711 countsByYear W26181447112021 @default.
• W2618144711 crossrefType "journal-article" @default.
• W2618144711 hasAuthorship W2618144711A5005354950 @default.
• W2618144711 hasAuthorship W2618144711A5007020077 @default.
• W2618144711 hasAuthorship W2618144711A5010967094 @default.
• W2618144711 hasAuthorship W2618144711A5016689216 @default.
• W2618144711 hasAuthorship W2618144711A5016760314 @default.
• W2618144711 hasAuthorship W2618144711A5018561595 @default.
• W2618144711 hasAuthorship W2618144711A5026279945 @default.
• W2618144711 hasAuthorship W2618144711A5026865203 @default.
• W2618144711 hasAuthorship W2618144711A5027937488 @default.
• W2618144711 hasAuthorship W2618144711A5034535532 @default.
• W2618144711 hasAuthorship W2618144711A5044878283 @default.
• W2618144711 hasAuthorship W2618144711A5052191965 @default.
• W2618144711 hasAuthorship W2618144711A5053330274 @default.
• W2618144711 hasAuthorship W2618144711A5055335263 @default.
• W2618144711 hasAuthorship W2618144711A5055443458 @default.
• W2618144711 hasAuthorship W2618144711A5061423789 @default.
• W2618144711 hasAuthorship W2618144711A5061712163 @default.
• W2618144711 hasAuthorship W2618144711A5062366315 @default.
• W2618144711 hasAuthorship W2618144711A5064622256 @default.
• W2618144711 hasAuthorship W2618144711A5077644935 @default.
• W2618144711 hasAuthorship W2618144711A5079102665 @default.
• W2618144711 hasAuthorship W2618144711A5087973639 @default.
• W2618144711 hasAuthorship W2618144711A5090129695 @default.
• W2618144711 hasConcept C126322002 @default.
• W2618144711 hasConcept C134018914 @default.
• W2618144711 hasConcept C197934379 @default.
• W2618144711 hasConcept C20251656 @default.
• W2618144711 hasConcept C2778248108 @default.
• W2618144711 hasConcept C2779902561 @default.
• W2618144711 hasConcept C2780644154 @default.
• W2618144711 hasConcept C2780854706 @default.
• W2618144711 hasConcept C62231903 @default.
• W2618144711 hasConcept C71924100 @default.
• W2618144711 hasConcept C90924648 @default.
• W2618144711 hasConcept C98274493 @default.
• W2618144711 hasConceptScore W2618144711C126322002 @default.
• W2618144711 hasConceptScore W2618144711C134018914 @default.
• W2618144711 hasConceptScore W2618144711C197934379 @default.
• W2618144711 hasConceptScore W2618144711C20251656 @default.
• W2618144711 hasConceptScore W2618144711C2778248108 @default.
• W2618144711 hasConceptScore W2618144711C2779902561 @default.
• W2618144711 hasConceptScore W2618144711C2780644154 @default.
• W2618144711 hasConceptScore W2618144711C2780854706 @default.
• W2618144711 hasConceptScore W2618144711C62231903 @default.
• W2618144711 hasConceptScore W2618144711C71924100 @default.
• W2618144711 hasConceptScore W2618144711C90924648 @default.
• W2618144711 hasConceptScore W2618144711C98274493 @default.
• W2618144711 hasIssue "22" @default.
• W2618144711 hasLocation W26181447111 @default.
• W2618144711 hasOpenAccess W2618144711 @default.
• W2618144711 hasPrimaryLocation W26181447111 @default.
• W2618144711 hasRelatedWork W1964395147 @default.
• W2618144711 hasRelatedWork W2092630182 @default.
• W2618144711 hasRelatedWork W2093972784 @default.
• W2618144711 hasRelatedWork W2323171152 @default.
• W2618144711 hasRelatedWork W2328388422 @default.
• W2618144711 hasRelatedWork W2330432969 @default.
• W2618144711 hasRelatedWork W2412859794 @default.
• W2618144711 hasRelatedWork W2413927684 @default.
• W2618144711 hasRelatedWork W2808641093 @default.

• next